The efficacy of adjuvant platinum-based chemotherapy in Stage I uterine papillary serous carcinoma (UPSC)

C. S. Dietrich, S. C. Modesitt, P. D. Depriest, F. R. Ueland, J. Wilder, M. B. Reedy, E. J. Pavlik, R. Kryscio, M. Cibull, J. Giesler, K. Manahan, W. Huh, D. Cohn, M. Powell, Brian Slomovitz, R. V. Higgins, W. Merritt, J. Hunter, L. Puls, P. GehrigJ. R. Van Nagell

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Objective. To determine the efficacy of adjuvant platinum-based chemotherapy in Stage I uterine papillary serous carcinoma (UPSC). Methods. A retrospective multi-institutional investigation was performed to identify surgically staged patients with Stage I UPSC who were (1) treated after surgery with 3-6 courses of platinum-based chemotherapy without radiation from 1990-2003, and (2) followed for a minimum of 12 months, or until recurrence. Results. Six patients (IA-2, IB-3, IC-1) were treated with carboplatin (AUC 6) or cisplatin (50 mg/m2) alone. One patient recurred to the vagina, was treated with chemo-radiation, and is alive and well at 122 months. One patient recurred to the lung, liver, and brain, and died of disease at 24 months. The remaining 4 patients are alive with no evidence of disease 15-124 months (mean 62 months) after treatment. Two patients (IB-1, IC-1) were treated with cisplatin (50 mg/m2) and cyclophosphamide (1000 mg/m 2), and both are alive and well with no evidence of disease 75 and 168 months after treatment. Twenty-one patients (IA-5, IB-13, IC-3) were treated with a combination of carboplatin (AUC 6) and paclitaxel (135 mg/m 2-175 mg/m2). One patient recurred to the vagina after 3 cycles of carboplatin/paclitaxel, and was treated with chemo-radiation. She is now without evidence of disease 10 months after treatment. At present, all 21 patients with Stage I UPSC treated following surgical staging with carboplatin/paclitaxel chemotherapy are alive and well with no evidence of disease 10-138 months (mean 41 months) after treatment. Conclusion. Combination carboplatin/paclitaxel chemotherapy following surgery is effective in the treatment of Stage I UPSC.

Original languageEnglish (US)
Pages (from-to)557-563
Number of pages7
JournalGynecologic Oncology
Volume99
Issue number3
DOIs
StatePublished - Dec 2005
Externally publishedYes

Fingerprint

Papillary Carcinoma
Platinum
Drug Therapy
Carboplatin
Paclitaxel
Vagina
Radiation
Cisplatin
Area Under Curve
Therapeutics
Brain Diseases
Cyclophosphamide
Recurrence
Lung
Liver

Keywords

  • Carboplatin
  • Paclitaxel
  • Uterine papillary serous carcinoma

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Dietrich, C. S., Modesitt, S. C., Depriest, P. D., Ueland, F. R., Wilder, J., Reedy, M. B., ... Van Nagell, J. R. (2005). The efficacy of adjuvant platinum-based chemotherapy in Stage I uterine papillary serous carcinoma (UPSC). Gynecologic Oncology, 99(3), 557-563. https://doi.org/10.1016/j.ygyno.2005.07.104

The efficacy of adjuvant platinum-based chemotherapy in Stage I uterine papillary serous carcinoma (UPSC). / Dietrich, C. S.; Modesitt, S. C.; Depriest, P. D.; Ueland, F. R.; Wilder, J.; Reedy, M. B.; Pavlik, E. J.; Kryscio, R.; Cibull, M.; Giesler, J.; Manahan, K.; Huh, W.; Cohn, D.; Powell, M.; Slomovitz, Brian; Higgins, R. V.; Merritt, W.; Hunter, J.; Puls, L.; Gehrig, P.; Van Nagell, J. R.

In: Gynecologic Oncology, Vol. 99, No. 3, 12.2005, p. 557-563.

Research output: Contribution to journalArticle

Dietrich, CS, Modesitt, SC, Depriest, PD, Ueland, FR, Wilder, J, Reedy, MB, Pavlik, EJ, Kryscio, R, Cibull, M, Giesler, J, Manahan, K, Huh, W, Cohn, D, Powell, M, Slomovitz, B, Higgins, RV, Merritt, W, Hunter, J, Puls, L, Gehrig, P & Van Nagell, JR 2005, 'The efficacy of adjuvant platinum-based chemotherapy in Stage I uterine papillary serous carcinoma (UPSC)', Gynecologic Oncology, vol. 99, no. 3, pp. 557-563. https://doi.org/10.1016/j.ygyno.2005.07.104
Dietrich, C. S. ; Modesitt, S. C. ; Depriest, P. D. ; Ueland, F. R. ; Wilder, J. ; Reedy, M. B. ; Pavlik, E. J. ; Kryscio, R. ; Cibull, M. ; Giesler, J. ; Manahan, K. ; Huh, W. ; Cohn, D. ; Powell, M. ; Slomovitz, Brian ; Higgins, R. V. ; Merritt, W. ; Hunter, J. ; Puls, L. ; Gehrig, P. ; Van Nagell, J. R. / The efficacy of adjuvant platinum-based chemotherapy in Stage I uterine papillary serous carcinoma (UPSC). In: Gynecologic Oncology. 2005 ; Vol. 99, No. 3. pp. 557-563.
@article{b0207ea5b5fa4aaeaaff5cfe2053df26,
title = "The efficacy of adjuvant platinum-based chemotherapy in Stage I uterine papillary serous carcinoma (UPSC)",
abstract = "Objective. To determine the efficacy of adjuvant platinum-based chemotherapy in Stage I uterine papillary serous carcinoma (UPSC). Methods. A retrospective multi-institutional investigation was performed to identify surgically staged patients with Stage I UPSC who were (1) treated after surgery with 3-6 courses of platinum-based chemotherapy without radiation from 1990-2003, and (2) followed for a minimum of 12 months, or until recurrence. Results. Six patients (IA-2, IB-3, IC-1) were treated with carboplatin (AUC 6) or cisplatin (50 mg/m2) alone. One patient recurred to the vagina, was treated with chemo-radiation, and is alive and well at 122 months. One patient recurred to the lung, liver, and brain, and died of disease at 24 months. The remaining 4 patients are alive with no evidence of disease 15-124 months (mean 62 months) after treatment. Two patients (IB-1, IC-1) were treated with cisplatin (50 mg/m2) and cyclophosphamide (1000 mg/m 2), and both are alive and well with no evidence of disease 75 and 168 months after treatment. Twenty-one patients (IA-5, IB-13, IC-3) were treated with a combination of carboplatin (AUC 6) and paclitaxel (135 mg/m 2-175 mg/m2). One patient recurred to the vagina after 3 cycles of carboplatin/paclitaxel, and was treated with chemo-radiation. She is now without evidence of disease 10 months after treatment. At present, all 21 patients with Stage I UPSC treated following surgical staging with carboplatin/paclitaxel chemotherapy are alive and well with no evidence of disease 10-138 months (mean 41 months) after treatment. Conclusion. Combination carboplatin/paclitaxel chemotherapy following surgery is effective in the treatment of Stage I UPSC.",
keywords = "Carboplatin, Paclitaxel, Uterine papillary serous carcinoma",
author = "Dietrich, {C. S.} and Modesitt, {S. C.} and Depriest, {P. D.} and Ueland, {F. R.} and J. Wilder and Reedy, {M. B.} and Pavlik, {E. J.} and R. Kryscio and M. Cibull and J. Giesler and K. Manahan and W. Huh and D. Cohn and M. Powell and Brian Slomovitz and Higgins, {R. V.} and W. Merritt and J. Hunter and L. Puls and P. Gehrig and {Van Nagell}, {J. R.}",
year = "2005",
month = "12",
doi = "10.1016/j.ygyno.2005.07.104",
language = "English (US)",
volume = "99",
pages = "557--563",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - The efficacy of adjuvant platinum-based chemotherapy in Stage I uterine papillary serous carcinoma (UPSC)

AU - Dietrich, C. S.

AU - Modesitt, S. C.

AU - Depriest, P. D.

AU - Ueland, F. R.

AU - Wilder, J.

AU - Reedy, M. B.

AU - Pavlik, E. J.

AU - Kryscio, R.

AU - Cibull, M.

AU - Giesler, J.

AU - Manahan, K.

AU - Huh, W.

AU - Cohn, D.

AU - Powell, M.

AU - Slomovitz, Brian

AU - Higgins, R. V.

AU - Merritt, W.

AU - Hunter, J.

AU - Puls, L.

AU - Gehrig, P.

AU - Van Nagell, J. R.

PY - 2005/12

Y1 - 2005/12

N2 - Objective. To determine the efficacy of adjuvant platinum-based chemotherapy in Stage I uterine papillary serous carcinoma (UPSC). Methods. A retrospective multi-institutional investigation was performed to identify surgically staged patients with Stage I UPSC who were (1) treated after surgery with 3-6 courses of platinum-based chemotherapy without radiation from 1990-2003, and (2) followed for a minimum of 12 months, or until recurrence. Results. Six patients (IA-2, IB-3, IC-1) were treated with carboplatin (AUC 6) or cisplatin (50 mg/m2) alone. One patient recurred to the vagina, was treated with chemo-radiation, and is alive and well at 122 months. One patient recurred to the lung, liver, and brain, and died of disease at 24 months. The remaining 4 patients are alive with no evidence of disease 15-124 months (mean 62 months) after treatment. Two patients (IB-1, IC-1) were treated with cisplatin (50 mg/m2) and cyclophosphamide (1000 mg/m 2), and both are alive and well with no evidence of disease 75 and 168 months after treatment. Twenty-one patients (IA-5, IB-13, IC-3) were treated with a combination of carboplatin (AUC 6) and paclitaxel (135 mg/m 2-175 mg/m2). One patient recurred to the vagina after 3 cycles of carboplatin/paclitaxel, and was treated with chemo-radiation. She is now without evidence of disease 10 months after treatment. At present, all 21 patients with Stage I UPSC treated following surgical staging with carboplatin/paclitaxel chemotherapy are alive and well with no evidence of disease 10-138 months (mean 41 months) after treatment. Conclusion. Combination carboplatin/paclitaxel chemotherapy following surgery is effective in the treatment of Stage I UPSC.

AB - Objective. To determine the efficacy of adjuvant platinum-based chemotherapy in Stage I uterine papillary serous carcinoma (UPSC). Methods. A retrospective multi-institutional investigation was performed to identify surgically staged patients with Stage I UPSC who were (1) treated after surgery with 3-6 courses of platinum-based chemotherapy without radiation from 1990-2003, and (2) followed for a minimum of 12 months, or until recurrence. Results. Six patients (IA-2, IB-3, IC-1) were treated with carboplatin (AUC 6) or cisplatin (50 mg/m2) alone. One patient recurred to the vagina, was treated with chemo-radiation, and is alive and well at 122 months. One patient recurred to the lung, liver, and brain, and died of disease at 24 months. The remaining 4 patients are alive with no evidence of disease 15-124 months (mean 62 months) after treatment. Two patients (IB-1, IC-1) were treated with cisplatin (50 mg/m2) and cyclophosphamide (1000 mg/m 2), and both are alive and well with no evidence of disease 75 and 168 months after treatment. Twenty-one patients (IA-5, IB-13, IC-3) were treated with a combination of carboplatin (AUC 6) and paclitaxel (135 mg/m 2-175 mg/m2). One patient recurred to the vagina after 3 cycles of carboplatin/paclitaxel, and was treated with chemo-radiation. She is now without evidence of disease 10 months after treatment. At present, all 21 patients with Stage I UPSC treated following surgical staging with carboplatin/paclitaxel chemotherapy are alive and well with no evidence of disease 10-138 months (mean 41 months) after treatment. Conclusion. Combination carboplatin/paclitaxel chemotherapy following surgery is effective in the treatment of Stage I UPSC.

KW - Carboplatin

KW - Paclitaxel

KW - Uterine papillary serous carcinoma

UR - http://www.scopus.com/inward/record.url?scp=28044434612&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28044434612&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2005.07.104

DO - 10.1016/j.ygyno.2005.07.104

M3 - Article

C2 - 16154185

AN - SCOPUS:28044434612

VL - 99

SP - 557

EP - 563

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -